Then, cobimetinib (MEK inhibitor), trametinib (MEK inhibitor), and dabrafenib (BRAF inhibitor) was approved by FDA to treat melanoma with BRAFV600 mutations, and trametinib and dabrafenib could also treat NSCLC with BRAFV600E mutation. The gene discussed is MAP2K7; the disease is melanoma.